Pfizer starts Omicron-specific COVID-19 vaccine trial
The Hindu
The trial will involve 1,420 people aged 18-55.
Pfizer and its partner BioNTech have begun enrolment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement on January 25.
Pfizer’s CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Wildfire smoke exposure increases lung cancer patients' risk of dying, especially for non-smokers, but certain treatments may help.
Discover how magma forms, bubbles, and leads to volcanic eruptions, including insights on dormant volcanoes like Uturuncu in Bolivia.
Telangana Formation Day celebration with Miss World 2025 Opal Suchata Chuangsri and global beauty pageant winners. Governor highlights cultural ethos.
Understanding the evolution of flowering plants through the SHUKR gene sheds light on plant adaptation and survival in changing environments.
Suzuki's 2025 e-Access electric scooter prioritizes practicality over flashiness, offering a calm, competent ride for urban commuters.
India's intensifying heat waves demand urgent action to protect health, economy, and communities from escalating impacts.
Tesla has been reeling from protests and boycotts over Musk wading into politics.
In Mallakhamb, a traditional performative sport from India, performers balance themselves on a pole and perform acrobatics.
The 72nd Miss World pageant in Hyderabad crowned Miss World 2025 after weeks of competition and cultural exchange.
Discover how lab-grown bat organoids and cell lines are revolutionizing virus research and pandemic preparedness worldwide.